干扰素诱导蛋白10在呼吸道病原微生物感染诊断和疾病监测中的研究进展

doi:10.19982/j.issn.1000-6621.20230400

摘要/Abstract

摘要：

干扰素诱导蛋白10(interferon inducible protein 10,IP-10)是Cys-X-Cys(CXC)趋化因子家族成员之一,其受体为CXCR3。IP-10具有多种生物学功能,如趋化T细胞、单核细胞、NK细胞在内的CXCR3⁺细胞到炎症部位发挥抗炎或促炎作用。研究发现,IP-10与呼吸道病原微生物感染及疾病进程相关,在结核感染的诊断,以及新型冠状病毒感染和高致病性禽流感等急性严重呼吸道感染性疾病进程的监测中发挥一定作用。因此,笔者主要围绕IP-10在各类呼吸道病原微生物感染的诊断及病程监测中的研究进展进行综述。

关键词: 干扰素诱导剂, 趋化因子类, 病原, 诊断

Abstract:

Interferon inducible protein 10 (IP-10) is a member of the Cys-X-Cys (CXC) chemokine family, and its receptor is CXCR3. IP-10 has multiple biological functions, such as CXCR3⁺ cells, including chemotactic T cells, monocytes and NK cells, play roles in the process of pro-inflammation or anti-inflammation. It was found that IP-10 is also associated with respiratory infectious diseases, it plays a certain role in the diagnosis of tuberculosis infection, as well as monitor the progress of acute and serious respiratory infectious diseases such as novel coronavirus infection and highly pathogenic avian influenza. Therefore, the progresses of IP-10 in the diagnosis and monitor of respiratory infectious diseases were reviewed in this article.

Key words: Interferon inducers, Chemotactic factors, Noxae, Diagnosis

中图分类号:

R52
R714.253

宋瑞雪, 姚明旭, 潘丽萍. 干扰素诱导蛋白10在呼吸道病原微生物感染诊断和疾病监测中的研究进展[J]. 中国防痨杂志, 2024, 46(4): 473-478. doi: 10.19982/j.issn.1000-6621.20230400

Song Ruixue, Yao Mingxu, Pan Liping. Research progresses of interferon-induced protein 10 in the diagnosis and monitor of respiratory infectious diseases[J]. Chinese Journal of Antituberculosis, 2024, 46(4): 473-478. doi: 10.19982/j.issn.1000-6621.20230400

参考文献 40

[1]	Cassatella MA, Gasperini S, Calzetti F, et al. Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol, 1997, 27(1): 111-115. doi:10.1002/eji.1830270117. pmid: 9022006
[2]	Luster AD, Ravetch JV. Genomic characterization of a gamma-interferon-inducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Mol Cell Biol, 1987, 7(10): 3723-3731. doi:10.1128/mcb.7.10.3723-3731.1987. pmid: 2824996
[3]	潘丽萍, 高孟秋, 贾红彦, 等. 新型结核分枝杆菌特异性细胞免疫反应检测技术对结核病辅助诊断的价值评估. 中华结核和呼吸杂志, 2021, 44(5): 443-449. doi:10.3760/cma.j.cn112147-20200821-00916.
[4]	Colvin RA, Campanella GS, Sun J, et al. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem, 2004, 279(29): 30219-30227. doi:10.1074/jbc.M403595200. pmid: 15150261
[5]	Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol, 1997, 61(3): 246-257. doi: 10.1002/jlb.61.3.246 URL
[6]	Campbell JD, Gangur V, Simons FE, et al. Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th 1 immunity-promoting loop. FASEB J, 2004, 18(2): 329-331. doi:10.1096/fj.02-0908fje. pmid: 14657006
[7]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[8]	Ruhwald M, Bjerregaard-Andersen M, Rabna P, et al. CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes Infect, 2007, 9(7): 806-812. doi:10.1016/j.micinf.2007.02.021. pmid: 17533146
[9]	Zhao Y, Yang X, Zhang X, et al. IP-10 and RANTES as biomarkers for pulmonary tuberculosis diagnosis and monitoring. Tuberculosis (Edinb), 2018, 111: 45-53. doi:10.1016/j.tube.2018.05.004.
[10]	Mamishi S, Mahmoudi S, Banar M, et al. Diagnostic accuracy of interferon (IFN)-γ inducible protein 10 (IP-10) as a biomarker for the discrimination of active and latent tuberculosis. Mol Biol Rep, 2019, 46(6):6263-6269. doi:10.1007/s11033-019-05067-0. pmid: 31564016
[11]	Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J, 2008, 32(6):1607-1615. doi:10.1183/09031936.00055508. pmid: 18684849
[12]	Qiu X, Tang Y, Yue Y, et al. Accuracy of interferon-γ-induced protein 10 for diagnosing latent tuberculosis infection: a systematic review and meta-analysis. Clin Microbiol Infect, 2019, 25(6):667-672. doi:10.1016/j.cmi.2018.12.006.
[13]	Blauenfeldt T, Heyckendorf J, Graff Jensen S, et al. Development of a one-step probe based molecular assay for rapid immunodiagnosis of infection with M.tuberculosis using dried blood spots. PLoS One, 2014, 9(9): e105628. doi:10.1371/journal.pone.0105628.
[14]	Pan L, Huang M, Jia H, et al. Diagnostic Performance of a Novel CXCL 10 mRNA Release Assay for Mycobacterium tuberculosis Infection. Front Microbiol, 2022, 13: 825413. doi:10.3389/fmicb.2022.825413.
[15]	宋瑞雪, 魏荣荣, 董静, 等. γ-干扰素诱导蛋白-10 mRNA检测技术对结核病辅助诊断的价值. 中国防痨杂志, 2023, 45(5):471-476. doi:10.19982/j.issn.1000-6621.20220518.
[16]	Lighter J, Rigaud M, Huie M, et al. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int J Tuberc Lung Dis, 2009, 13(6):731-736. pmid: 19460249
[17]	Latorre I, Díaz J, Mialdea I, et al. IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children. J Infect, 2014, 69(6):590-599. doi:10.1016/j.jinf.2014.06.013. pmid: 24975172
[18]	Kabeer BS, Sikhamani R, Raja A. Comparison of interferon gamma-inducible protein-10 and interferon gamma-based QuantiFERON TB Gold assays with tuberculin skin test in HIV-infected subjects. Diagn Microbiol Infect Dis, 2011, 71(3): 236-243. doi:10.1016/j.diagmicrobio.2011.07.012.
[19]	Goletti D, Raja A, Syed Ahamed Kabeer B, et al. Is IP-10 an accurate marker for detecting M.tuberculosis-specific response in HIV-infected persons? PLoS One, 2010, 5(9): e12577. doi:10.1371/journal.pone.0012577.
[20]	Tang Y, Yu Y, Wang Q, et al. Evaluation of the IP-10 mRNA release assay for diagnosis of TB in HIV-infected individuals. Front Cell Infect Microbiol, 2023, 13: 1152665. doi:10.3389/fcimb.2023.1152665.
[21]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5. pmid: 31986264
[22]	Chen Y, Wang J, Liu C, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med, 2020, 26(1):97. doi:10.1186/s10020-020-00230-x. pmid: 33121429
[23]	Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, 323(11):1061-1069. doi:10.1001/jama.2020.1585. pmid: 32031570
[24]	Yang Y, Shen C, Li J, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol, 2020, 146(1):119-127.e4. doi:10.1016/j.jaci.2020.04.027. pmid: 32360286
[25]	Wu X, Xiao L, Li L. Research progress on human infection with avian influenza H7N9. Front Med, 2020, 14(1):8-20. doi:10.1007/s11684-020-0739-z.
[26]	Chi Y, Zhu Y, Wen T, et al. Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China. J Infect Dis, 2013, 208(12):1962-1967. doi:10.1093/infdis/jit440. pmid: 23990573
[27]	Huang R, Zhang L, Gu Q, et al. Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9. PLoS One, 2014, 9(7): e101788. doi:10.1371/journal.pone.0101788.
[28]	Ng PC, Lam CW, Li AM, et al. Chemokine response in children with SARS. Arch Dis Child, 2005, 90(4):422-423. doi:10.1136/adc.2004.053660. pmid: 15781938
[29]	Ward SE, Loutfy MR, Blatt LM, et al. Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids. Antivir Ther, 2005, 10(2):263-275. pmid: 15865221
[30]	中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版). 中华结核和呼吸杂志, 2016, 39(4): 253-279. doi:10.3760/cma.j.issn.1001-0939.2016.04.005.
[31]	van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet, 2009, 374(9700):1543-1556. doi:10.1016/S0140-6736(09)61114-4. pmid: 19880020
[32]	Zou J, Zhou L, Hu C, et al. IL-8 and IP-10 expression from human bronchial epithelial cells BEAS-2B are promoted by Streptococcus pneumoniae endopeptidase O (PepO). BMC Microbiol, 2017, 17(1):187. doi:10.1186/s12866-017-1081-8. pmid: 28836948
[33]	Meyer Sauteur PM, Krautter S, Ambroggio L, et al. Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children. Clin Infect Dis, 2020, 71(7):1645-1654. doi:10.1093/cid/ciz1059.
[34]	苏晓宇, 陈信, 王磊, 等. 动态肺功能异常与肺炎支原体肺炎患儿慢性咳嗽相关性研究. 临床军医杂志, 2022, 50(12):1265-1267. doi:10.16680/j.1671-3826.2022.12.16.
[35]	Venge P, Eriksson S, Pauksen K. Blood biomarker algorithms for the diagnosis of mycoplasma pneumoniae respiratory infections. J Immunol Methods, 2021, 489: 112908. doi:10.1016/j.jim.2020.112908.
[36]	Li M, Chen Y, Li H, et al. Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children. BMC Infect Dis, 2021, 21(1): 909. doi:10.1186/s12879-021-06632-4.
[37]	Wang G, Zhao G, Chao X, et al. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae. Int J Environ Res Public Health, 2020, 17(17): 6278. doi:10.3390/ijerph17176278.
[38]	Zeng X, Moore TA, Newstead MW, et al. Interferon-inducible protein 10, but not monokine induced by gamma interferon, promotes protective type 1 immunity in murine Klebsiella pneumoniae pneumonia. Infect Immun, 2005, 73(12): 8226-8236. doi:10.1128/IAI.73.12.8226-8236.2005. pmid: 16299319
[39]	Miller RF, Huang L, Walzer PD. Pneumocystis pneumonia associated with human immunodeficiency virus. Clin Chest Med, 2013, 34(2):229-241. doi:10.1016/j.ccm.2013.02.001. pmid: 23702173
[40]	McAllister F, Ruan S, Steele C, et al. CXCR3 and IFN protein-10 in Pneumocystis pneumonia. J Immunol, 2006, 177(3):1846-1854. doi:10.4049/jimmunol.177.3.1846. pmid: 16849496